BioNxt Solutions Receivables 2020-2025 | BNXTF

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BioNxt Solutions receivables from 2020 to 2025. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BioNxt Solutions receivables from 2020 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$70.5B
Zoetis (ZTS)	$69.4B
Takeda Pharmaceutical (TAK)	$49.4B
Daiichi Sankyo, - (DSNKY)	$48.3B
BeOne Medicines - (ONC)	$34.4B
Sandoz Group AG (SDZNY)	$27.6B
Summit Therapeutics (SMMT)	$19.5B
Merck (MKKGY)	$17B
Shionogi (SGIOY)	$14.9B
United Therapeutics (UTHR)	$14.1B
Neurocrine Biosciences (NBIX)	$13.4B
IPSEN (IPSEY)	$11.4B
Orion OYJ (ORINY)	$11.3B
Eisai (ESAIY)	$9.3B
Madrigal Pharmaceuticals (MDGL)	$9.2B
Corcept Therapeutics (CORT)	$7.4B
Grifols, S.A (GRFS)	$7B
Stevanato Group S.p.A (STVN)	$6.9B
Ionis Pharmaceuticals (IONS)	$6.8B
Ono Pharmaceutical (OPHLF)	$5.7B
Hikma Pharmaceuticals Plc (HKMPF)	$5.4B
Soleno Therapeutics (SLNO)	$3.6B
Procaps Group, S.A (PROCF)	$3.2B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$3B
Crinetics Pharmaceuticals (CRNX)	$2.9B
NewAmsterdam Pharma (NAMS)	$2.8B
Catalyst Pharmaceuticals (CPRX)	$2.6B
Hypermarcas (HYPMY)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.3B
Ocular Therapeutix (OCUL)	$2.1B